Published in Urology on February 07, 2010
Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system. Can Urol Assoc J (2011) 1.11
A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clin Proc (2012) 0.89
Asymptomatic microscopic hematuria in women requires separate guidelines. Int Urogynecol J (2012) 0.79
The clinical usefulness of nuclear matrix protein-22 in patients with atypical urine cytology. Korean J Urol (2011) 0.76
Author response: Microscopic hematuria and urothelial malignancy. Can Urol Assoc J (2014) 0.75
Utility of urine cytology in evaluating hematuria with sonographically suspected bladder lesion in patients older than 50 years. Urol Ann (2014) 0.75
Editorial comment. Urology (2010) 0.75
Re: Feifer et al.: Utility of urine cytology in workup of asymptomatic microscopic hematuria in low-risk patients (Urology 2010;75:1278-1282). Urology (2011) 0.75
Editorial comment. Urology (2010) 0.75
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J (2011) 2.50
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol (2010) 2.11
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J (2009) 2.00
Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol (2006) 1.97
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int (2011) 1.85
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther (2009) 1.80
Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol (2004) 1.76
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol (2012) 1.65
Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer (2010) 1.65
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol (2008) 1.54
Length of prostate biopsy cores: does it impact cancer detection? Can J Urol (2013) 1.54
The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. J Endourol (2011) 1.53
Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int (2011) 1.50
Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol (2009) 1.49
Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol (2007) 1.49
Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations. Urology (2004) 1.47
Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int (2012) 1.46
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol (2005) 1.45
An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec. Can Urol Assoc J (2008) 1.45
Agents of non-gonococcal urethritis in males attending an Israeli clinic for sexually transmitted diseases. Isr Med Assoc J (2003) 1.44
Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J (2008) 1.42
Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Urology (2010) 1.42
An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol (2009) 1.42
Are men on 5α-reductase inhibitors appropriately referred to urology? A survey of primary care physicians. BJU Int (2010) 1.41
Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol (2010) 1.40
Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer (2007) 1.39
Incorporation of the da Vinci Surgical Skills Simulator at urology Objective Structured Clinical Examinations (OSCEs): a pilot study. Can J Urol (2016) 1.39
The unsuspected nonpalpable testicular mass detected by ultrasound: a management problem. Can J Urol (2003) 1.39
Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int (2010) 1.31
Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations. Clin Nutr (2013) 1.26
Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol (2006) 1.26
Primary leiomyosarcoma of the kidney: a clinicopathologic study of 27 cases. Am J Surg Pathol (2010) 1.25
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.21
Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol (2007) 1.21
Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. Can Urol Assoc J (2010) 1.21
Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncol Pract (2013) 1.21
Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer (2007) 1.20
Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation. Can Urol Assoc J (2007) 1.19
Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol (2011) 1.18
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res (2010) 1.15
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int (2010) 1.15
Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther (2009) 1.15
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol (2003) 1.13
Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system. Can Urol Assoc J (2011) 1.11
Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol (2010) 1.11
Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.10
The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer (2010) 1.10
Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urol (2005) 1.10
From podium to press: The 10-year publication rate of abstracts presented at the annual meetings of the Quebec Urological Association (QUA). Can Urol Assoc J (2013) 1.08
Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One (2011) 1.07
Renal cell carcinoma with inferior vena caval extention: impact of tumour extent on surgical outcome. BJU Int (2009) 1.07
Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology (2002) 1.07
Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Can Urol Assoc J (2011) 1.07
Dietary habits and prostate cancer detection: a case-control study. Can Urol Assoc J (2008) 1.06
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol (2010) 1.06
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol (2010) 1.04
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J (2013) 1.04